Hansoh Pharmaceutical Group Company Limited (3692.HK)

18.300 +0.060 (+0.33%) At close: 04:08PM HKT

Hansoh Pharmaceutical Group Company Limited

287 Xiangke Road
Pudong New District
Shanghai 201210
China
86 40 0828 5227
https://www.hspharm.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 9,123

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Huijuan Zhong	Chairlady, CEO & President	12.02M	N/A	1961
Mr. Aifeng Lyu	Executive Director	2.73M	N/A	1977
Ms. Yuan Sun	Executive Director	7.4M	N/A	1987
Mr. Min Hu	VP & CFO	N/A	N/A	1977
Mr. Chuanhe Xu	Senior Vice President	N/A	N/A	1964
Mr. Weiyong Sun	Chief Commercial Officer	N/A	N/A	1971
Ms. Shengli Zhong	Joint Company Secretary & Senior VP	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Corporate governance

Hansoh Pharmaceutical Group Company Limited’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.